We are analyzing https://link.springer.com/article/10.1007/s00262-025-04082-4.

Title:
Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9 | Cancer Immunology, Immunotherapy
Description:
Objective This study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8+ T cells in chronic lymphocytic leukemia (CLL) through IL-9. Methods Peripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis between ILC2s and IL-9 was conducted using the Spearman test. ILC2s were sorted and cultured from CLL patients, followed by co-culture experiments with PBMCs of healthy controls and MEC-1 cells, with or without anti-IL-9 antibody intervention. Flow cytometry was used to measure the proportions of ILC2s, Treg cells, PD-1+/TIGIT+/CTLA-4+ Treg subsets, and granzyme B+/perforin+ CD8+ T cells, along with MEC-1 cell apoptosis. Results The proportions of ILC2s and Treg, along with serum IL-9 levels, were significantly elevated in CLL patients (P < 0.05). Peripheral blood ILC2s were positively correlated with IL-9 (r = 0.609, P < 0.001). The average fluorescence intensity of GATA3, CRTH2, and IL-9 in the cervical lymph nodes of CLL patients increased significantly (P < 0.001), and IL-9 showed colocalization with GATA3 and CRTH2. In vitro, IL-9 levels in the supernatant of sorted ILC2s from CLL patients increased. Treatment with anti-IL-9 antibody significantly reduced the PD-1+ Treg and TIGIT+ Treg cells while increasing granzyme B+ CD8+ T cells (P < 0.05). However, there was no significant effect on Treg, CTLA-4+ Treg, and perforin+ CD8+ T cells (P > 0.05). Additionally, anti-IL-9 antibody significantly increased early apoptosis (P < 0.05). Conclusion ILC2s affect CD8+ T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8+ T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cells, ilcs, pubmed, treg, cll, article, cell, google, scholar, patients, cas, blood, central, group, peripheral, cancer, healthy, antibody, immune, min, fig, analysis, lymphocytic, innate, chronic, levels, flow, apoptosis, tigit, data, study, control, mec, antiil, tumor, leukemia, cytometry, granzyme, results, function, controls, lymph, significantly, immunol, regulatory, china, culture, lymphoid, samples, supernatant,

Topics {✒️}

cd45+lin−cd127+crth2+cd117+ cells magnetic bead negative selection strategy b-cell lymphoproliferative disorders chronic lymphocytic leukaemia cd45+lin−cd127+crth2+cd117+ anti-pd-1/pd-l1 immunotherapy chronic lymphocytic leukemia anti-apoptotic protein bcl3 nkp30-b7h6 engagement drives immunosuppressive properties compared article download pdf small lymphocytic lymphoma anti-tumor immune response innate lymphoid cells immunosuppressive ilc2-mdsc axis anti-il-9 antibody stimulation resistance-independent treatment methods adaptive foxp3+cd4+ regulatory anti-il-9 antibody compared pd-1+/tigit+/ctla-4+ treg subsets helminth-induced lung inflammation anti-il-9 antibody intervention anti-il-9 antibody leads anti-il-9 antibodies resulted pd-1/pd-l1 inhibitors immune regulation mechanism co2-free culture chamber il-9-producing cells cmt167 mouse model granzyme b-ecd innate immune response stat6 activation promotes related subjects jianhua qu interpreted jianhua qu revised lymph node biopsy privacy choices/manage cookies anti-tumor responses chronic liver diseases healthy control-derived pbmcs annexin v-fitc t-cell transformation program death-1 signaling full access inhibiting immune responses small sample size anti-il-9 antibody sting/ilc2 axis cervical lymph node tgf-beta signaling

Questions {❓}

Cavagnero KJ, Doherty TA (2020) ILC2s: Are they what we think they are?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9
         description:This study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8+ T cells in chronic lymphocytic leukemia (CLL) through IL-9. Peripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis between ILC2s and IL-9 was conducted using the Spearman test. ILC2s were sorted and cultured from CLL patients, followed by co-culture experiments with PBMCs of healthy controls and MEC-1 cells, with or without anti-IL-9 antibody intervention. Flow cytometry was used to measure the proportions of ILC2s, Treg cells, PD-1+/TIGIT+/CTLA-4+ Treg subsets, and granzyme B+/perforin+ CD8+ T cells, along with MEC-1 cell apoptosis. The proportions of ILC2s and Treg, along with serum IL-9 levels, were significantly elevated in CLL patients (P < 0.05). Peripheral blood ILC2s were positively correlated with IL-9 (r = 0.609, P < 0.001). The average fluorescence intensity of GATA3, CRTH2, and IL-9 in the cervical lymph nodes of CLL patients increased significantly (P < 0.001), and IL-9 showed colocalization with GATA3 and CRTH2. In vitro, IL-9 levels in the supernatant of sorted ILC2s from CLL patients increased. Treatment with anti-IL-9 antibody significantly reduced the PD-1+ Treg and TIGIT+ Treg cells while increasing granzyme B+ CD8+ T cells (P < 0.05). However, there was no significant effect on Treg, CTLA-4+ Treg, and perforin+ CD8+ T cells (P > 0.05). Additionally, anti-IL-9 antibody significantly increased early apoptosis (P < 0.05). ILC2s affect CD8+ T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8+ T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.
         datePublished:2025-05-30T00:00:00Z
         dateModified:2025-05-30T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by-nc-nd/4.0/
         sameAs:https://doi.org/10.1007/s00262-025-04082-4
         keywords:
            Chronic lymphocytic leukemia
            Type 2 innate lymphoid cells (ILC2s)
            IL-9
            Regulatory T cells (Treg)
            CD8+ T cells
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig6_HTML.png
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
            volumeNumber:74
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ruixue Yang
               affiliation:
                     name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                     address:
                        name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xuejiao Zeng
               affiliation:
                     name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                     address:
                        name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xierenguli Alimu
               affiliation:
                     name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                     address:
                        name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jianhua Qu
               affiliation:
                     name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                     address:
                        name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9
      description:This study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8+ T cells in chronic lymphocytic leukemia (CLL) through IL-9. Peripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis between ILC2s and IL-9 was conducted using the Spearman test. ILC2s were sorted and cultured from CLL patients, followed by co-culture experiments with PBMCs of healthy controls and MEC-1 cells, with or without anti-IL-9 antibody intervention. Flow cytometry was used to measure the proportions of ILC2s, Treg cells, PD-1+/TIGIT+/CTLA-4+ Treg subsets, and granzyme B+/perforin+ CD8+ T cells, along with MEC-1 cell apoptosis. The proportions of ILC2s and Treg, along with serum IL-9 levels, were significantly elevated in CLL patients (P < 0.05). Peripheral blood ILC2s were positively correlated with IL-9 (r = 0.609, P < 0.001). The average fluorescence intensity of GATA3, CRTH2, and IL-9 in the cervical lymph nodes of CLL patients increased significantly (P < 0.001), and IL-9 showed colocalization with GATA3 and CRTH2. In vitro, IL-9 levels in the supernatant of sorted ILC2s from CLL patients increased. Treatment with anti-IL-9 antibody significantly reduced the PD-1+ Treg and TIGIT+ Treg cells while increasing granzyme B+ CD8+ T cells (P < 0.05). However, there was no significant effect on Treg, CTLA-4+ Treg, and perforin+ CD8+ T cells (P > 0.05). Additionally, anti-IL-9 antibody significantly increased early apoptosis (P < 0.05). ILC2s affect CD8+ T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8+ T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.
      datePublished:2025-05-30T00:00:00Z
      dateModified:2025-05-30T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by-nc-nd/4.0/
      sameAs:https://doi.org/10.1007/s00262-025-04082-4
      keywords:
         Chronic lymphocytic leukemia
         Type 2 innate lymphoid cells (ILC2s)
         IL-9
         Regulatory T cells (Treg)
         CD8+ T cells
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-025-04082-4/MediaObjects/262_2025_4082_Fig6_HTML.png
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
         volumeNumber:74
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ruixue Yang
            affiliation:
                  name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                  address:
                     name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xuejiao Zeng
            affiliation:
                  name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                  address:
                     name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xierenguli Alimu
            affiliation:
                  name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                  address:
                     name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jianhua Qu
            affiliation:
                  name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
                  address:
                     name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
      volumeNumber:74
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
      address:
         name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
         type:PostalAddress
      name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
      address:
         name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
         type:PostalAddress
      name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
      address:
         name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
         type:PostalAddress
      name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
      address:
         name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ruixue Yang
      affiliation:
            name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
            address:
               name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
               type:PostalAddress
            type:Organization
      name:Xuejiao Zeng
      affiliation:
            name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
            address:
               name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
               type:PostalAddress
            type:Organization
      name:Xierenguli Alimu
      affiliation:
            name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
            address:
               name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
               type:PostalAddress
            type:Organization
      name:Jianhua Qu
      affiliation:
            name:Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region
            address:
               name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
      name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
      name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China
      name:Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi, China

External Links {🔗}(267)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.64s.

LINK . SPRINGER . COM {}